L-Carnitine's Effect On The Biomarkers Of Metabolic Syndrome: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials
Notes for this study:
||cm. Mean change and 95% CI: -1.89 (-3.14, -0.64)
|Number of Subjects
This was a meta-analysis of randomized, controlled trials investigating the effects of l-carnitine for at least two weeks on metabolic syndrome outcomes, including waist circumference, blood pressure, fasting glucose, triglycerides, and HDL. The studies had to be without the use of other drugs. It included 9 trials that included 508 participants. Doses ranged from 0.75 to 3 g per day and 2 g was the most common dose.
The studies weren't generally at a high risk of bias, but none stood out as particularly rigorous. Based on two studies, there was a statistically significant reduction in waist circumference and systolic but not quite diastolic blood pressure. There was a statistically reduction in fasting glucose, triglycerides, and anHDL increase based on 5-6 studies, though the differences weren't statistically significant. The subgroup analysis found greater effects for more severe metabolic syndrome and greater effects for higher carnitine doses, but the comparisons were based on few studies.